We are upgrading the repository! A content freeze is in effect until November 22nd, 2024 - no new submissions will be accepted; however, all content already published will remain publicly available. Please reach out to repository@u.library.arizona.edu with your questions, or if you are a UA affiliate who needs to make content available soon. Note that any new user accounts created after September 22, 2024 will need to be recreated by the user in November after our migration is completed.
Improving the Affordability of Prescription Medications for People with Chronic Respiratory Disease. An Official American Thoracic Society Policy Statement
Name:
Managing the Price of Prescription ...
Size:
267.3Kb
Format:
PDF
Description:
Final Accepted Manuscript
Author
Patel, Minal R.Press, Valerie G.
Gerald, Lynn B.
Barnes, Teresa
Blake, Kathryn
Brown, Lee K.
Costello, Richard W.
Crim, Courtney
Forshag, Mark
Gershon, Andrea S.
Goss, Christopher H.
Han, MeiLan K.
Lee, Todd A.
Sweet, Stuart
Gerald, Joe K.
Affiliation
Univ Arizona Hlth Sci, Asthma & Airway Dis Res CtrUniv Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Dept Community Environm & Policy
Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Dept Hlth Promot Sci
Issue Date
2018-12-01
Metadata
Show full item recordPublisher
AMER THORACIC SOCCitation
Patel, M. R., Press, V. G., Gerald, L. B., Barnes, T., Blake, K., Brown, L. K., ... & Goss, C. H. (2018). Improving the Affordability of Prescription Medications for People with Chronic Respiratory Disease. An Official American Thoracic Society Policy Statement. American journal of respiratory and critical care medicine, 198(11), 1367-1374.Rights
© 2018 by the American Thoracic Society.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Background: Mounting evidence indicates that out-of-pocket costs for prescription medications, particularly among low- and middle-income patients with chronic diseases, are imposing financial burden, reducing medication adherence, and worsening health outcomes. This problem is exacerbated by a paucity of generic alternatives for prevalent lung diseases, such as asthma and chronic obstructive pulmonary disease, as well as high-cost medicines for rare diseases, such as cystic fibrosis. Affordability and access challenges are especially salient in the United States, as citizens of many other countries pay lower prices for and have greater access to prescription medications. Methods: The American Thoracic Society convened a multidisciplinary committee comprising experts in health policy pharmacoeconomics, behavioral sciences, and clinical care, along with individuals providing industry and patient perspectives. The report and its recommendation were iteratively developed over a year of in-person, telephonic, and electronic deliberation. Results: The committee unanimously recommended the establishment of a publicly funded, politically independent, impartial entity to systematically draft evidence-based pharmaceutical policy recommendations. The goal of this entity would be to generate evidence and action steps to ensure people have equitable and affordable access to prescription medications, to maximize the value of public and private pharmaceutical expenditures on health, to support novel drug development within a market-based economy, and to preserve clinician and patient choice regarding personalized treatment. An immediate priority is to examine the evidence and make recommendations regarding the need to have essential medicines with established clinical benefit from each drug class in all Tier 1 formularies and propose recommendations to reduce barriers to timely generic drug availability. Conclusions: By making explicit, evidence-based recommendations, the entity can support the establishment of coherent national policies that expand access to affordable medications, improve the health of patients with chronic disease, and optimize the use of public and private resources.Note
12 month embargo; published 1 December 2018ISSN
1073-449X1535-4970
Version
Final accepted manuscriptSponsors
American Thoracic SocietyAdditional Links
https://www.atsjournals.org/doi/10.1164/rccm.201810-1865STae974a485f413a2113503eed53cd6c53
10.1164/rccm.201810-1865ST